-
Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation
•
On November 22, China General Technology (Group) Holding released three official announcements through its official channels, all concerning the investigation of senior executives at Henan Topfond Pharmaceutical Co., Ltd. (SHA: 600253). The details are as follows: Background on Henan Topfond PharmaceuticalEstablished in 1969, Henan Topfond Pharmaceutical is a large-scale comprehensive…
-
China Meheco Group Appoints Yang Guang as Chairman and Legal Representative
•
China Meheco Group Co., Ltd (SHA: 600056) has announced the appointment of Yang Guang to the pivotal roles of chairman and legal representative of the company. In addition to these roles, Yang will also assume the chairmanship of the Strategy and Investment Committee and serve as a member of the…
-
Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services
•
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco International Co., Ltd, a wholly-owned subsidiary of China Meheco Group Co., Ltd. The collaboration will focus on project cooperation and investment, leveraging the comprehensive advantages of both companies in information, knowledge, talent, products, and channels…
-
Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China
•
China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered into a partnership with UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) to handle the import and distribution of Evusheld (tixagevimab, cilgavimab) in mainland China. Evusheld is a COVID-19 prophylactic neutralizing antibody combination designed to provide…
-
China Meheco to Import and Distribute Pfizer’s Paxlovid in Mainland China
•
China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer that will allow the former to import and distribute Pfizer’s COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) in mainland China from December 14, 2022, to November 30, 2023. No financial details were disclosed. Paxlovid: Indications and Market…
